Evoke Pharma Stock Price Patterns
| EVOK Stock | USD 25.70 0.30 1.15% |
Momentum 67
Buy Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.30) | EPS Estimate Current Year (1.88) | EPS Estimate Next Year 0.68 | Wall Street Target Price 18 | EPS Estimate Current Quarter (0.45) |
Using Evoke Pharma hype-based prediction, you can estimate the value of Evoke Pharma from the perspective of Evoke Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Evoke Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Evoke because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Evoke Pharma after-hype prediction price | USD 29.02 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Evoke Pharma Basic Forecasting Models to cross-verify your projections. Evoke Pharma After-Hype Price Density Analysis
As far as predicting the price of Evoke Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Evoke Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Evoke Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Evoke Pharma Estimiated After-Hype Price Volatility
In the context of predicting Evoke Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Evoke Pharma's historical news coverage. Evoke Pharma's after-hype downside and upside margins for the prediction period are 13.28 and 44.76, respectively. We have considered Evoke Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Evoke Pharma is moderately volatile at this time. Analysis and calculation of next after-hype price of Evoke Pharma is based on 3 months time horizon.
Evoke Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Evoke Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evoke Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Evoke Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.14 | 15.74 | 3.32 | 0.39 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
25.70 | 29.02 | 12.92 |
|
Evoke Pharma Hype Timeline
Evoke Pharma is currently traded for 25.70. The entity has historical hype elasticity of 3.32, and average elasticity to hype of competition of 0.39. Evoke is estimated to increase in value after the next headline, with the price projected to jump to 29.02 or above. The average volatility of media hype impact on the company the price is over 100%. The price upswing on the next news is projected to be 12.92%, whereas the daily expected return is currently at 2.14%. The volatility of related hype on Evoke Pharma is about 8690.8%, with the expected price after the next announcement by competition of 26.09. Evoke Pharma currently holds 5.16 M in liabilities with Debt to Equity (D/E) ratio of 0.7, which is about average as compared to similar companies. Evoke Pharma has a current ratio of 10.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Evoke Pharma's use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next estimated press release will be in about 8 days. Check out Evoke Pharma Basic Forecasting Models to cross-verify your projections.Evoke Pharma Related Hype Analysis
Having access to credible news sources related to Evoke Pharma's direct competition is more important than ever and may enhance your ability to predict Evoke Pharma's future price movements. Getting to know how Evoke Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Evoke Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| YCBD | cbdMD Inc | 0.01 | 6 per month | 7.74 | 0.06 | 21.17 | (14.98) | 112.24 | |
| BFRI | Biofrontera | (0.02) | 9 per month | 0.00 | (0.06) | 6.76 | (7.59) | 34.13 | |
| SBFM | Sunshine Biopharma | 0.03 | 6 per month | 0.00 | (0.20) | 4.35 | (5.37) | 13.93 | |
| SNOA | Sonoma Pharmaceuticals | (0.09) | 8 per month | 0.00 | (0.13) | 5.03 | (4.37) | 19.00 | |
| ADIL | Adial Pharmaceuticals | (0.22) | 8 per month | 0.00 | (0.31) | 5.70 | (8.24) | 34.48 | |
| MHUA | Meihua International Medical | 2.02 | 8 per month | 0.00 | (0.01) | 27.69 | (25.45) | 60.20 | |
| NRSN | Neurosense Therapeutics | 0.01 | 9 per month | 0.00 | (0.02) | 12.82 | (7.48) | 34.62 | |
| SSKN | STRATA Skin Sciences | (0.06) | 7 per month | 0.00 | (0.16) | 7.35 | (7.30) | 18.95 | |
| BMRA | Biomerica | (0.05) | 7 per month | 0.00 | (0.1) | 4.12 | (5.21) | 18.44 |
Evoke Pharma Additional Predictive Modules
Most predictive techniques to examine Evoke price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Evoke using various technical indicators. When you analyze Evoke charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Evoke Pharma Predictive Indicators
The successful prediction of Evoke Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Evoke Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Evoke Pharma based on analysis of Evoke Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Evoke Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Evoke Pharma's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 0.12 | 0.17 | 0.2 | 0.25 | Days Of Inventory On Hand | 871.17 | 455.65 | 524.0 | 619.04 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Evoke Pharma Basic Forecasting Models to cross-verify your projections. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.38) | Revenue Per Share | Quarterly Revenue Growth 0.614 | Return On Assets | Return On Equity |
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.